Page 1: UNITED STATES
Page 2: PACIRA PHARMACEUTICALS, INC.
Page 3: PART I. FINANCIAL INFORMATION
Page 4: PACIRA PHARMACEUTICALS, INC.
Page 5: PACIRA PHARMACEUTICALS, INC.
Page 6: PACIRA PHARMACEUTICALS, INC.
Page 7: PACIRA PHARMACEUTICALS, INC.
Page 8: PACIRA PHARMACEUTICALS, INC.
Page 9: Prompt pay reserve
Page 10: Note 3 FINANCIAL INSTRUMENTS
Page 11: Credit Risk
Page 12: Note 6 GOODWILL AND INTANGIBLE ASSETS
Page 13: Note 7 DEBT AND FINANCING OBLIGATIONS
Page 14: Subsequent Events
Page 15: Stock Incentive Plans
Page 16: Note 10 RELATED PARTY TRANSACTIONS
Page 17: Item 2. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 18: Results of Operations
Page 19: Cost of Revenues
Page 20: Selling, General and Administrative Expense
Page 21: Liquidity and Capital Resources
Page 22: Investing Activities
Page 23: Off-Balance Sheet Arrangements
Page 24: Prompt pay reserve
Page 25: Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Page 26: PART II OTHER INFORMATION
Page 27: The design, development, manufacture, supply, and distribution of EXPAREL and DepoCyt(e) is highly r
Page 28: If we fail to comply with federal and state healthcare laws, including fraud and abuse and health in
Page 29: We are subject to new legislation, regulatory proposals and healthcare payer initiatives that may in
Page 30: We have incurred significant losses since our inception and anticipate that we will incur continued
Page 31: Our principal stockholders and management own a significant percentage of our stock and will be able
Page 32: Item 6. EXHIBITS
Page 33: SIGNATURES